Related references
Note: Only part of the references are listed.A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study
Laura K. Ferris et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS)
D. Thaci et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
Kristian Reich et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis
Yaowei Zhu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Assessing Efficacy and the Speed of Response in Psoriasis Treatment
Jeremy G. Light et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2019)
Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study
O. Nemoto et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
A safety evaluation of guselkumab for the treatment of psoriasis
M. Galluzzo et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2018)
The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: An observational cohort study
Jashin J. Wu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment
Tom C. Chan et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2018)
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Jason E. Hawkes et al.
JOURNAL OF IMMUNOLOGY (2018)
Association of Psoriasis With Inflammatory Bowel Disease A Systematic Review and Meta-analysis
Yun Fu et al.
JAMA DERMATOLOGY (2018)
Psoriasis and Cardiovascular Diseases: A Literature Review to Determine the Causal Relationship
Shanu Jindal et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2018)
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies
K. B. Gordon et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC
A. Nast et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression
J. Koo et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab
Tiago Torres
DRUGS (2017)
Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
George E. Fragoulis et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions
Tina Bhutani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Definition of treatment goals for moderate to severe psoriasis: a European consensus
U. Mrowietz et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2011)
The Risk of Depression, Anxiety, and Suicidality in Patients With Psoriasis A Population-Based Cohort Study
Shanu Kohli Kurd et al.
ARCHIVES OF DERMATOLOGY (2010)
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database
Nehal N. Mehta et al.
EUROPEAN HEART JOURNAL (2010)
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Antonella Di Cesare et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IL-23 promotes tumour incidence and growth
John L. Langowski et al.
NATURE (2006)
In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin
G Piskin et al.
JOURNAL OF IMMUNOLOGY (2006)
IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12
MA Kleinschek et al.
JOURNAL OF IMMUNOLOGY (2006)
Psoriasis treatment: current and emerging directed therapies
LS Winterfield et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris
E Lee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Share Paper
